ABSTRACT
GPR40 mediates free fatty acid-induced insulin secretion in beta cells. We investigated the safety, pharmacokinetics, and glucose response of MK-8666, a partial GPR40 agonist, after once-daily multiple dosing in type 2 diabetes patients. This double-blind, multisite, parallel-group study randomized 63 patients (placebo, n = 18; 50 mg, n = 9; 150 mg, n = 18; 500 mg, n = 18) for 14-day treatment. The results showed no serious adverse effects or treatment-related hypoglycemia. One patient (150-mg group) showed mild-to-moderate transaminitis at the end of dosing. Median MK-8666 Tmax was 2.0-2.5 h and mean apparent terminal half-life was 22-32 h. On Day 15, MK-8666 reduced fasting plasma glucose by 54.1 mg/dL (500 mg), 36.0 mg/dL (150 mg), and 30.8 mg/dL (50 mg) more than placebo, consistent with translational pharmacokinetic/pharmacodynamic model predictions. Maximal efficacy for longer-term assessment is projected at 500 mg based on exposure-response analysis. In conclusion, MK-8666 was generally well tolerated with robust glucose-lowering efficacy.
Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Receptors, G-Protein-Coupled/antagonists & inhibitors , Adult , Aged , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Dose-Response Relationship, Drug , Endpoint Determination , Humans , Least-Squares Analysis , Middle Aged , Models, Biological , Proof of Concept Study , Receptors, G-Protein-Coupled/metabolism , Treatment OutcomeABSTRACT
A microdose cocktail containing midazolam, dabigatran etexilate, pitavastatin, rosuvastatin, and atorvastatin has been established to allow simultaneous assessment of a perpetrator impact on the most common drug metabolizing enzyme, cytochrome P450 (CYP)3A, and the major transporters organic anion-transporting polypeptides (OATP)1B, breast cancer resistance protein (BCRP), and MDR1 P-glycoprotein (P-gp). The clinical utility of these microdose cocktail probe substrates was qualified by conducting clinical drug interaction studies with three inhibitors with different in vitro inhibitory profiles (rifampin, itraconazole, and clarithromycin). Generally, the pharmacokinetic profiles of the probe substrates, in the absence and presence of the inhibitors, were comparable to their reported corresponding pharmacological doses, and/or in agreement with theoretical expectations. The exception was dabigatran, which resulted in an approximately twofold higher magnitude for microdose compared to conventional dosing, and, thus, can be used to flag a worst-case scenario for P-gp. Broader application of the microdose cocktail will facilitate a more comprehensive understanding of the roles of drug transporters in drug disposition and drug interactions.
Subject(s)
Carrier Proteins/metabolism , Cytochrome P-450 CYP3A/metabolism , Drug Combinations , Drug Interactions , ATP Binding Cassette Transporter, Subfamily B/metabolism , ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism , Adult , Area Under Curve , Carrier Proteins/antagonists & inhibitors , Cell Line , Cytochrome P-450 CYP3A Inhibitors/adverse effects , Cytochrome P-450 CYP3A Inhibitors/therapeutic use , Drug-Related Side Effects and Adverse Reactions/enzymology , Drug-Related Side Effects and Adverse Reactions/metabolism , Female , Healthy Volunteers , Humans , Liver-Specific Organic Anion Transporter 1/metabolism , Male , Middle Aged , Neoplasm Proteins/metabolism , Pharmacokinetics , Tissue Distribution , Young AdultABSTRACT
γ-Secretase mediates amyloid production in Alzheimer's disease (AD) and oncogenic activity of Notch. γ-Secretase inhibitors (GSIs) are thus of interest for AD and oncology. A peripheral biomarker of Notch activity would aid determination of the therapeutic window and dosing regimen for GSIs, given toxicities associated with chronic Notch inhibition. This study examined the effects of GSI MK-0752 on blood and hair follicle transcriptomes in healthy volunteers. The effects of a structurally diverse GSI on rhesus blood and hair follicles were also compared. Significant dose-related effects of MK-0752 on transcription were observed in hair follicles, but not blood. The GSI biomarker identified in follicles exhibited 100% accuracy in a clinical test cohort, and was regulated in rhesus by a structurally diverse GSI. This study identified a translatable, accessible pharmacodynamic biomarker of GSI target engagement and provides proof of concept of hair follicle RNA as a translatable biomarker source.
Subject(s)
Amyloid Precursor Protein Secretases/antagonists & inhibitors , Benzene Derivatives/pharmacology , Drug Monitoring , Hair Follicle/drug effects , Propionates/pharmacology , Protease Inhibitors/pharmacology , Receptors, Notch/antagonists & inhibitors , Sulfones/pharmacology , Transcription, Genetic/drug effects , Adolescent , Adult , Amyloid Precursor Protein Secretases/metabolism , Animals , Baltimore , Benzene Derivatives/administration & dosage , Benzene Derivatives/blood , Benzene Derivatives/pharmacokinetics , Biomarkers, Pharmacological/blood , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Drug Monitoring/methods , Gene Expression Profiling/methods , Hair Follicle/metabolism , Healthy Volunteers , Humans , Macaca mulatta , Male , Models, Animal , Molecular Targeted Therapy , Oligonucleotide Array Sequence Analysis , Propionates/administration & dosage , Propionates/blood , Propionates/pharmacokinetics , Protease Inhibitors/administration & dosage , Protease Inhibitors/blood , Protease Inhibitors/pharmacokinetics , RNA, Messenger/biosynthesis , RNA, Messenger/blood , Receptors, Notch/metabolism , Sulfones/administration & dosage , Sulfones/blood , Sulfones/pharmacokinetics , Young AdultABSTRACT
Human papillomavirus (HPV) causes cervical, vulvar, and vaginal cancers, precancerous dysplasia, and genital warts. We report data for the longest efficacy evaluation to date of a prophylactic HPV vaccine. In total, 552 women (16-23 years) were enrolled in a randomised, placebo-controlled study of a quadrivalent HPV 6/11/16/18 L1 virus-like-particle vaccine with vaccination at months 0, 2, and 6. At regular intervals through 3 years, subjects underwent gynaecologic examination, cervicovaginal sampling for HPV DNA, serum anti-HPV testing, and Pap testing, with follow-up biopsy as indicated. A subset of 241 subjects underwent two further years of follow-up. At 5 years post enrollment, the combined incidence of HPV 6/11/16/18-related persistent infection or disease was reduced in vaccine-recipients by 96% (two cases vaccine versus 46 placebo). There were no cases of HPV 6/11/16/18-related precancerous cervical dysplasia or genital warts in vaccine recipients, and six cases in placebo recipients (efficacy = 100%; 95% CI:12-100%). Through 5 years, vaccine-induced anti-HPV geometric mean titres remained at or above those following natural infection. In conclusion, a prophylactic quadrivalent HPV vaccine was effective through 5 years for prevention of persistent infection and disease caused by HPV 6/11/16/18. This duration supports vaccination of adolescents and young adults, which is expected to greatly reduce the burden of cervical and genital cancers, precancerous dysplasia, and genital warts.
Subject(s)
Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/immunology , Papillomavirus Vaccines/therapeutic use , Uterine Cervical Neoplasms/prevention & control , Virion/immunology , Adolescent , Adult , Alphapapillomavirus/immunology , Antibodies, Viral/blood , Condylomata Acuminata/prevention & control , Double-Blind Method , Female , Follow-Up Studies , Humans , Incidence , Papillomavirus Infections/epidemiology , Uterine Cervical Dysplasia/prevention & control , Vaginal SmearsABSTRACT
The Mantel-Haenszel (M-H) procedure is commonly used to compare two treatments in a stratified binomial trial. However, this procedure is asymptotically optimal only if the odds ratio is constant across strata. We propose an alternative analytic strategy based on the simultaneous use of two statistics, ZS and ZI, each involving a weighted averaging of within-stratum differences between proportions. The two treatments are declared significantly different at overall level alpha if either min(ZS, ZI) > Zalpha/2 or max(ZS, ZI) > Zalpha*/2, where alpha* is data dependent. Our strategy is shown to be more powerful than the M-H and other related procedures. Numerical examples are provided for illustration.
Subject(s)
Binomial Distribution , Data Interpretation, Statistical , Randomized Controlled Trials as Topic/statistics & numerical data , Adrenergic beta-Antagonists/therapeutic use , Aged , Humans , Metoprolol/therapeutic use , Middle Aged , Myocardial Infarction/drug therapy , Myocardial Infarction/mortality , Sample Size , Treatment OutcomeABSTRACT
When comparing two treatments in a stratified trial with a binary endpoint, data are commonly analysed using a weighted averaging of the stratum-specific differences between proportions. Two popular sets of weights are the harmonic means of the stratum-specific sample sizes (SSIZE) and the reciprocals of the variances of the stratum-specific differences (INVAR). Either the SSIZE or INVAR weights are chosen and prespecified in the data analysis plan. We show that the 'wrong' choice between SSIZE and INVAR can result in a significantly inefficient analysis. To circumvent this potential problem, we propose a 'minimum risk' (MR) weighting strategy. The easy-to-compute MR weights are designed to yield more precise and less biased estimates of the overall treatment difference relative to the SSIZE and INVAR weights, respectively. We show, via a simulation study, that the proposed weights are an attractive compromise between the SSIZE and INVAR weights in terms of statistical power. Numerical examples are presented to illustrate the utility of the MR weights.